Open AccessImplementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures
Author(s) -
Alexandra U. Scherrer,
Viktor von Wyl,
Christof A Fux,
Milos Opravil,
Heiner C. Bucher,
Aurélie Fayet,
Laurent A. Décosterd,
B Hirschel,
Bettina Khanlari,
Sabine Yerly,
Thomas Klimkait,
Hansjakob Furrer,
Bruno Ledergerber,
Huldrych F. Günthard
Publication year - 2010
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3181bca4ec
Subject(s) - raltegravir , medicine , enfuvirtide , viral load , odds ratio , regimen , confidence interval , clinical trial , randomized controlled trial , logistic regression , maraviroc , ritonavir , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , antigen , gp41 , epitope
Raltegravir (RAL) achieved remarkable virologic suppression rates in randomized-clinical trials, but today efficacy data and factors for treatment failures in a routine clinical care setting are limited.